Kuwait Pharmaceutical market, 2018 – 2033 (USD Million) UAE Pharmaceutical market, 2018 – 2033 (USD Million)12.6.5. Saudi Arabia Pharmaceutical market, 2018 – 2033 (USD Million)12.6.4. South Africa Pharmaceutical market, 2018 – 2033 (USD Million)12.6.3. MEA Pharmaceutical market, 2018 – 2033 (USD Million)12.6.2.
US Prescription Drugs Market Growth Factors
Latin America Pharmaceutical market, 2018 – 2033 (USD Million)12.5.2. Thailand Pharmaceutical market, 2018 – 2033 (USD Million)12.5. Australia Pharmaceutical market, 2018 – 2033 (USD Million)12.4.7.
Pharmaceutical Drugs Global Market Report 2025
The 2025–2026 projections for traditional drugs are similar to 2024–2025 estimates, boosted by new therapies, manufacturer price increases, and steady utilization gains in top categories, particularly diabetes. Traditional drug trends rose significantly as the effects of insulin price decreases and several substantial generic entries have passed. Mercer Government’s Pharmacy team (Mercer), consisting of consultants and licensed pharmacists, monitors market and pipeline developments to incorporate real-time insights into our analyses. Supportive regulatory changes, growing health insurance coverage, and the rise of domestic pharmaceutical manufacturers are key drivers enhancing drug availability and affordability across the nation.
In An Emergency? Need Treatment?
The countries of drug production and transit are some of the most affected by the trade, though countries receiving the illegally imported substances are also adversely affected. This gave the United States military broad authority to employ military force against drug cartels and to target their leaders through direct military action. In 2025, by executive order, the United States expanded its approach in its counter drug campaign to designate foreign drug cartels as foreign terrorist organizations. In December 2005, Van Tuong Nguyen, a 25-year-old Australian drug smuggler, was hanged in Singapore after being convicted in March 2004. As a result, international organized crime syndicates such as the Sinaloa Cartel and 'Ndrangheta have increased cooperation among each other in order to facilitate trans-Atlantic drug-trafficking.
Generic Drugs Market Size, Research, Trends And Forecast
The rate of penetration of obesity drugs is estimated to jump from about 1% currently to 10% of the obese population in the next 10 years, reaching a total market of $70 billion. The U.S. is currently the biggest market in the world for obesity drugs, with about 8 million patients. Public healthcare coverage in the U.S. through Medicare should also broaden as these drugs are approved for obesity-related co-morbidities. Sales volume should increase as the drugs begin to treat a wider array of diseases. According to the new estimates, about 11% of the global eligible population of 1.3 billion people could be on obesity drugs, including 20% of eligible patients in the U.S. and 10% in other countries.
Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions.
Share Content
In China, there is a rising emphasis on healthcare, resulting in a raised demand for pharmaceuticals, including traditional Chinese medicine. Although novel advanced technologies in drug delivery, including nanotechnology, microencapsulation, and 3D printing, are optimizing drug efficacy and bioavailability, which leads to the enhanced demand for drugs. Moreover, the boosting of healthcare expenditure and government commitments to universal healthcare assure a continued demand for pharmaceutical products. This segment is experiencing demand due to contributing factors such as, it is convenience, approachability, and reasonable cost. These are prescribed drugs, which are used in complex, chronic, and rare conditions like cancer, multiple sclerosis, rheumatoid arthritis, and other diseases.
- During a drug shortage, healthcare providers and pharmacies may face challenges maintaining a consistent supply of brand-name medications.
- This figure will likely increase significantly in the coming years due to the costs of developing effective and safe COVID-19 treatments and vaccines.
- Technological integration in healthcare delivery and increased digital prescription usage are further stimulating market growth in both inpatient and outpatient settings.
- As drug producers gained more power, they became more centralized and organized into what became drug cartels.
Pharmaceutical Analytical Testing Market Size To Hit USD 21 Bn By 2034
The government of Brazil is widely focusing on enhancing public health, and the availability of medications is escalating the market. Moreover, they are incorporating technological advancements in drug delivery, including self-injection devices and novel systems, which are enhancing patient convenience and outcomes. One more significantly rising factor is that India is a leading provider of generic medicines, with inexpensive production facilities.
What Made The Branded Drugs Segment Dominate The Market In 2024?
Cervicorn Consulting, based in India and the U.S., is a market research and consulting firm. GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc. in May 2022 to strengthen its vaccine R&D pipeline, gain access to new technologies, and expand its geographic reach in the Boston area. In the LAMEA region, which comprises nations like Argentina, Brazil, Mexico, the United Arab Emirates, Saudi Arabia, Africa, and others the pharmaceutical sector has expanded dramatically. Furthermore, during the projected period, higher sales of medications and vaccines for chronic illnesses are also anticipated to fuel the growth.
Artificial intelligence (AI) can play a vital role in developing novel generic drugs by suggesting excipients required for preparing a formulation. In the U.S., despite accounting for only 3% of total healthcare spending, they offer significant cost savings compared to brand-name drugs. This indicates a shift in the pattern of spending on generic drugs during this period. Firstly, the expiration of patents on brand-name drugs creates an opportunity for generic drug manufacturers to enter the market and offer more affordable alternatives.
These elements collectively underscore the market's robust potential and its critical role in meeting the healthcare demands of the future. The major players are focusing on increasing their R&D investments for the development process of novel therapies to meet the unmet demand of the patient population. The market in the LAMEA region is continuing to expand owing to population growth, a rise in chronic illnesses, better access to healthcare, and a growing healthcare infrastructure.
At present, around 620 million people worldwide are living with heart and circulatory diseases, and it is estimated that around 60 million new cases of cardiovascular diseases are reported annually. Cardiovascular disorders are a major public health concern for individuals globally. Increased funding facilitates market entry strategies, such as conducting market assessments, obtaining necessary licenses, and adapting products to meet specific regional requirements. Adequate funding enables manufacturers to navigate the regulatory landscape and gain necessary approvals for their generic products. This promotes competition and helps drive down drug prices, making medications more affordable for patients. The list is updated every six months to promote transparency and encourage competition in markets with limited alternatives.
Europe Poised For Strong Growth In Generic Pharmaceuticals As Awareness Rises
As APAC becomes a key hub for drug manufacturing and clinical trials, the affordability and accessibility of prescription medications continue to improve across both urban and rural areas. Government initiatives to improve healthcare infrastructure and promote access to essential medicines are encouraging pharmaceutical expansion across the region. In addition, increased adoption of telehealth, e-prescriptions, and the growing prevalence of chronic and lifestyle-related conditions further propel the U.S. market. The immunology segment is expected to register the fastest CAGR of 8.1% from 2025 to 2032, owing to increasing cases of autoimmune disorders and advancements in biologics. The oncology segment held the largest market share of 28.3% in 2024, driven by high cancer prevalence and rising adoption of targeted therapies. The market is segmented on the basis of type, therapy area, route of administration, end user, and distribution channel
Continuous Manufacturing (CM)
On the basis of route of administration, the prescription drugs market is segmented into oral, topical, parenteral, and others. On the basis of therapy area, the prescription drugs market is segmented into oncology, immunology, ophthalmology, respiratory, dermatology, gastroenterology, urology, gynaecology, endocrinology, and others. Dr. Steve Slilaty, CEO of Sunshine Biopharma, commented that the launch of two generic drugs could fulfill the company’s commitment to expand its presence in the Canadian generic drug market.
